Literature DB >> 9589642

Effects of human growth hormone, insulin-like growth factor I, and diet and exercise on body composition of obese postmenopausal women.

J L Thompson1, G E Butterfield, U K Gylfadottir, J Yesavage, R Marcus, R L Hintz, A Pearman, A R Hoffman.   

Abstract

To determine the effects of GH and insulin-like growth factor I (IGF-I) administration, diet, and exercise on weight loss, body composition, basal metabolic rate (BMR), muscle strength, and psychological status, 33 moderately obese postmenopausal women (67.1 +/- 5.2 yr) participated in a 12-week randomized, double blind study. Participants were placed on a diet that provided 500 Cal/day less than that needed for weight maintenance, and they walked 3 days and strength trained 2 days each week. Subjects also self-injected GH (0.025 mg/kg BW.day), IGF-I (0.015 mg/kg BW.day), a combination of these doses of GH and IGF-I, or placebo (P). Twenty-eight women completed the study, as five subjects dropped out due to intolerable side-effects (e.g. edema). Weight loss occurred in all groups, with the largest decrease occurring in the GH plus IGF-I group (5.6 +/- 1.4 kg). Fat mass significantly decreased in all groups, with the largest losses observed in GH and GH plus IGF-I groups (6.3 +/- 1.8 and 8.4 +/- 2.8 kg, respectively). Despite weight loss, BMR was maintained in all groups. Muscle strength increased with training for all groups, and depression and anxiety scores decreased in groups receiving IGF-I. These data show that obese postmenopausal women can lose weight and fat without compromising fat free mass, BMR, or gains in muscle strength, and that GH and IGF-I given together may enhance fat loss over either given alone.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9589642     DOI: 10.1210/jcem.83.5.4826

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  17 in total

Review 1.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

Review 2.  Validated treatments and therapeutics prospectives regarding pharmacological products for sarcopenia.

Authors:  G Onder; C Della Vedova; F Landi
Journal:  J Nutr Health Aging       Date:  2009-10       Impact factor: 4.075

Review 3.  Osteosarcopenia: where bone, muscle, and fat collide.

Authors:  H P Hirschfeld; R Kinsella; G Duque
Journal:  Osteoporos Int       Date:  2017-07-22       Impact factor: 4.507

Review 4.  Cardiovascular risk in aging and obesity: is there a role for GH.

Authors:  M Gola; S Bonadonna; M Doga; G Mazziotti; A Giustina
Journal:  J Endocrinol Invest       Date:  2005-09       Impact factor: 4.256

Review 5.  Managing sarcopenia and its related-fractures to improve quality of life in geriatric populations.

Authors:  Tetsuro Hida; Atsushi Harada; Shiro Imagama; Naoki Ishiguro
Journal:  Aging Dis       Date:  2013-11-26       Impact factor: 6.745

Review 6.  Optimal management of sarcopenia.

Authors:  Louise A Burton; Deepa Sumukadas
Journal:  Clin Interv Aging       Date:  2010-09-07       Impact factor: 4.458

7.  Bioavailable insulin-like growth factor-I inversely related to weight gain in postmenopausal women regardless of exogenous estrogen.

Authors:  Su Yon Jung; Stephen D Hursting; Michele Guindani; Mara Z Vitolins; Electra Paskett; Shine Chang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-12-20       Impact factor: 4.254

Review 8.  Modulation of GH/IGF-1 axis: potential strategies to counteract sarcopenia in older adults.

Authors:  Silvia Giovannini; Emanuele Marzetti; Stephen E Borst; Christiaan Leeuwenburgh
Journal:  Mech Ageing Dev       Date:  2008-08-13       Impact factor: 5.432

Review 9.  Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives.

Authors:  Y Rolland; S Czerwinski; G Abellan Van Kan; J E Morley; M Cesari; G Onder; J Woo; R Baumgartner; F Pillard; Y Boirie; W M C Chumlea; B Vellas
Journal:  J Nutr Health Aging       Date:  2008 Aug-Sep       Impact factor: 4.075

10.  Carla Task Force on Sarcopenia: propositions for clinical trials.

Authors:  G Abellan van Kan; E André; H A Bischoff Ferrari; Y Boirie; G Onder; M Pahor; P Ritz; Y Rolland; C Sampaio; S Studenski; M Visser; B Vellas
Journal:  J Nutr Health Aging       Date:  2009-10       Impact factor: 4.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.